Scholarlink

Background <p>Clinical trials (CTs) play a crucial role in developing new cancer treatments and enhancing patient outcomes. However, being part of these trials remains low across many regions, including the middle east and north Africa region (MENA). This study aims to evaluate the knowledge and attitudes of the general population regarding cancer clinical trials and to examine determinants of limited awareness and unfavorable attitudes.</p> Methods <p>A multinational cross-sectional study was conducted from March 1 to May 31, 2024, initially involving 5,528 participants, with a final sample of 5,422 respondents after data cleaning. Data was collected using a standard population-based cross-sectional survey, distributed both online via Google Forms and in-person. Convenience sampling was employed, with Countries and centers were selected based on accessibility, willingness to participate, and representation of different healthcare systems across the MENA region. Data analysis was conducted using Jamovi 2.3.28 software.</p> Results <p>Of the 5,422 responses, significant participation was observed from Egypt (22.9%) and Bahrain (20.9%). Knowledge of CTs was moderate overall, with 63.5% of participants being familiar with the concept; however, only 9.1% exhibited a high level of knowledge. Attitudes toward CT participation were largely unfavorable, with 83.8% of respondents expressing reluctance to participate, despite 77.6% indicating an interest in receiving more information about CTs. Multinomial logistic regression indicated that private and governmental employees had higher knowledge levels compared to unemployed individuals(OR = 1.65, p = 0.007, and OR = 1.87, <i>p &lt; </i>0.001, respectively). Participants with chronic illnesses and those with prior research participation also demonstrated high knowledge(OR = 2.92, <i>p &lt; </i>0.001). Attitude scores, on the other hand, were significantly correlated with age and gender (<i>p &lt; </i>0.003). Sperman’s revealed a positive correlation between knowledge and attitude indicating that higher knowledge levels are associated with more favorable attitudes.</p> Conclusion <p>This study provides insights into the general knowledge and attitude toward cancer clinical trials among the MENA population while identifying significant gaps in understanding and willingness to participate. The findings highlight the necessity of targeted educational interventions and public awareness campaigns to enhance knowledge about clinical trials and encourage a more favorable attitude toward participation. </p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Knowledge and attitudes toward cancer clinical trials: a multi-national cross-sectional study in the Middle East and North Africa

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月27日

查看全文
  • Israa Ahmed Qutob,
  • Abdullrahman Elgarawany,
  • Hoda Aufy,
  • Asmaa Soliman,
  • Baraa M.Ayesh,
  • Ahmed Abdelaziz Eldaly,
  • Sally Muhamed Seliem,
  • Rayhana Trabelsi,
  • Farah Tarek Shaalan,
  • Fatema Shehab,
  • Ali Salah Elgahamy,
  • Rola Nail Marie,
  • Ahmed I. S. Alnatsha,
  • Farah Mohamed Ismail Hamdan,
  • Abd El-Rahman Shaltout,
  • Qais AlNjoom,
  • Fatema Ebrahim Hamza,
  • Noor Zakareya Isa,
  • Mujtabi Reyadh Ali Aljamri,
  • Engy Mohamed Flifel,
  • Kassab Kenza,
  • Fathia Bougafa,
  • Siham Mohamed Abdi,
  • Saja E. Abusabha,
  • Yasmeen Adawi,
  • Malak Hameda,
  • Hadeel Khaled Albaoni,
  • Abdulrazak Baroudi,
  • Esraa Awad,
  • Noha Osman Frere

摘要

Background

Clinical trials (CTs) play a crucial role in developing new cancer treatments and enhancing patient outcomes. However, being part of these trials remains low across many regions, including the middle east and north Africa region (MENA). This study aims to evaluate the knowledge and attitudes of the general population regarding cancer clinical trials and to examine determinants of limited awareness and unfavorable attitudes.

Methods

A multinational cross-sectional study was conducted from March 1 to May 31, 2024, initially involving 5,528 participants, with a final sample of 5,422 respondents after data cleaning. Data was collected using a standard population-based cross-sectional survey, distributed both online via Google Forms and in-person. Convenience sampling was employed, with Countries and centers were selected based on accessibility, willingness to participate, and representation of different healthcare systems across the MENA region. Data analysis was conducted using Jamovi 2.3.28 software.

Results

Of the 5,422 responses, significant participation was observed from Egypt (22.9%) and Bahrain (20.9%). Knowledge of CTs was moderate overall, with 63.5% of participants being familiar with the concept; however, only 9.1% exhibited a high level of knowledge. Attitudes toward CT participation were largely unfavorable, with 83.8% of respondents expressing reluctance to participate, despite 77.6% indicating an interest in receiving more information about CTs. Multinomial logistic regression indicated that private and governmental employees had higher knowledge levels compared to unemployed individuals(OR = 1.65, p = 0.007, and OR = 1.87, p < 0.001, respectively). Participants with chronic illnesses and those with prior research participation also demonstrated high knowledge(OR = 2.92, p < 0.001). Attitude scores, on the other hand, were significantly correlated with age and gender (p < 0.003). Sperman’s revealed a positive correlation between knowledge and attitude indicating that higher knowledge levels are associated with more favorable attitudes.

Conclusion

This study provides insights into the general knowledge and attitude toward cancer clinical trials among the MENA population while identifying significant gaps in understanding and willingness to participate. The findings highlight the necessity of targeted educational interventions and public awareness campaigns to enhance knowledge about clinical trials and encourage a more favorable attitude toward participation.